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A mesenchymal transition occurs both during the
natural evolution of glioblastoma (GBM) and in
response to therapy. Here, we report that the adhe-
sion G-protein-coupled receptor, GPR56/ADGRG1,
inhibits GBMmesenchymal differentiation and radio-
resistance. GPR56 is enriched in proneural and clas-
sical GBMs and is lost during their transition toward a
mesenchymal subtype. GPR56 loss of function pro-
motes mesenchymal differentiation and radioresist-
ance of glioma initiating cells both in vitro and in vivo.
Accordingly, a low GPR56-associated signature
is prognostic of a poor outcome in GBM patients
even within non-G-CIMP GBMs. Mechanistically,
we reveal GPR56 as an inhibitor of the nuclear factor
kappa B (NF-kB) signaling pathway, thereby
providing the rationale by which this receptor pre-
vents mesenchymal differentiation and radioresist-
ance. A pan-cancer analysis suggests that GPR56
might be an inhibitor of the mesenchymal transition
across multiple tumor types beyond GBM.Cell Repor
This is an open access article under the CC BY-NINTRODUCTION
Glioblastomas (GBMs) are the most frequent and aggressive pri-
mary tumors in the central nervous systemowing to their fast clin-
ical course and uniform lethality (Dunn et al., 2012; Louis et al.,
2016). Adult GBMs can be classified according to their gene
expression and epigenetic profiles into five different subtypes
as follows: glioma-CpG island methylator phenotype (G-CIMP)
and four non-G-CIMP subtypes termed proneural (PN), neural,
classical (CL), and mesenchymal (MES) (Brennan et al., 2013;
Noushmehr et al., 2010; Verhaak et al., 2010). G-CIMP GBMs
are tightly associated with somatic mutations in the IDH1 or
IDH2 genes (Parsons et al., 2008; Yan et al., 2009) and show a
more favorable prognosis, whereas non-G-CIMP GBM patients
have the poorest prognosis (Noushmehr et al., 2010) with the
MES subtype correlating with higher radioresistance and shorter
survival (Bhat et al., 2013; Patel et al., 2014).
Non-G-CIMP GBMs display elevated transcriptional plasticity
and have an intrinsic ability to transition from one subtype
to another. The best characterized of these transitions is the
PN-to-MES transition (PMT), which is associated with tumor
recurrence (Phillips et al., 2006) and acquired resistance to
anti-angiogenic therapy (Piao et al., 2013). Along the same lines,ts 21, 2183–2197, November 21, 2017 ª 2017 The Author(s). 2183
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
non-G-CIMPGBMs, includingMES-GBMs, have been proposed
to evolve from a common PN-like precursor glioma during GBM
evolution (Ozawa et al., 2014). Analogous to whole tumors, iso-
lated tumor cell cultures that are enriched in glioma stem-like
initiating cells (GICs) also display the GBM-subtype-specific
phenotypes (Bhat et al., 2013; Mao et al., 2013; Patel et al.,
2014; Xie et al., 2015). Nonetheless, GICs are highly plastic
and also undergo transitions from PN to MES identity, especially
in response to inflammation or ionizing radiation (Bhat et al.,
2013; Halliday et al., 2014; Mao et al., 2013; Segerman et al.,
2016). Although we and others have identified some of the mo-
lecular mediators that promote MES differentiation, such as nu-
clear factor kappa B (NF-kB) (Bhat et al., 2013), the negative
modulators of this process remain unknown. Deciphering the
molecular mechanisms that control MES differentiation is of
crucial interest to understand both GBM natural evolution as
well as acquired resistance to therapy.
The acquisition of aMESphenotype inGBMhas been linked to
the activation of master transcription factors and co-factors that
control an epithelial-to-mesenchymal transition (EMT) such as
STAT3, C/EBPb, and TAZ (Bhat et al., 2011; Bundy and Sealy,
2003; Carro et al., 2010; Chen et al., 2014; Lei et al., 2008; Lo
et al., 2007; Xiong et al., 2012). During EMT, either in embryonic
development or in tumorigenesis, epithelial cells lose polarity,
reduce cellular adhesion, and increase cell migration (Mani
et al., 2008; Thiery et al., 2009). In a large number of systems,
the loss of cell adhesion that is required to initiate EMT is
achieved through the repression of the epithelial marker E-cad-
herin, which is a transmembrane calcium-dependent glycopro-
tein that is responsible for cell-to-cell adhesion. However, limited
expression of E-cadherin in normal brain tissue and GBMs sug-
gests that other adhesion proteins might be playing a role in this
process (Lewis-Tuffin et al., 2010).
Adhesion G-protein-coupled receptors (GPCRs), which are an
atypical class of GPCRs, are characterized by an unusually long
extracellular domain that is involved in cell-to-cell and cell-to-
extracellular matrix interactions (Langenhan et al., 2013). Several
adhesion-GPCRs, including GPR56/ADGRG1, are highly ex-
pressed in the brain. In the present study, we investigated the
role of GPR56 in GBM pathogenesis by integrating the analysis
of clinical specimens with functional assays in GICs and identi-
fied the role of GPR56 as an inhibitor of MES differentiation.
GPR56 knockdown promotesMES differentiation of GICs, which
is accompanied by increased radioresistance both in vitro and
in vivo. Accordingly, a low GPR56-associated signature is
prognostic of a poor outcome in non-G-CIMP GBM patients.
Furthermore, we identified GPR56 as an inhibitor of the NF-kB
signaling pathway, and pan-cancer analyses suggested that
this receptor might have an analogous function in other cancer
types beyond GBM.
RESULTS
GPR56 Is Downregulated in MES-GBMs and Inversely
Correlated with MES Markers in GBM Specimens
To identify inhibitors of MES differentiation in GBMs, we
searched within the class of adhesion-GPCRs for receptors
that are differentially expressed across GBM subtypes. We2184 Cell Reports 21, 2183–2197, November 21, 2017reasoned that potential inhibitors of MES differentiation would
be downregulated in MES-GBMs with respect to other sub-
types. We analyzed mRNA expression of the 33 adhesion-
GPCR members in GBM specimens from The Cancer Genome
Atlas (TCGA) dataset (Brennan et al., 2013). A group-compari-
son analysis between the five different GBM subtypes revealed
the downregulation of four adhesion-GPCRs in MES-GBMs
versus the rest of GBM subtypes: GPR56, BAI1, BAI3, and
CELSR3 (Figures 1A and S1). Among these, GPR56 emerged
as a promising candidate since its biological functions in the
context of a normal brain pointed to a possible role in counter-
acting an EMT-like process. This receptor serves as an extra-
cellular matrix receptor that mediates the attachment of radial
glial progenitors to the pial basement membrane (Li et al.,
2008), while it inhibits the migration of neural progenitors and
invasion and metastasis in other tumor types, especially mela-
noma (Luo et al., 2011; Xu et al., 2006, 2010). Furthermore,
GPR56 has a crucial role in brain development (Bae et al.,
2014; Piao et al., 2004) and is highly expressed in neural
stem cells (NSCs) and oligodendrocyte progenitor cells
(OPCs) (Ackerman et al., 2015; Giera et al., 2015; Jeong
et al., 2012), which are two proposed cells of origin of GBM (Al-
cantara Llaguno et al., 2015; Liu et al., 2011).
We next analyzed the correlation between GPR56 expression
and published PN or MES signatures (Verhaak et al., 2010). As
expected, GPR56 mRNA levels were positively and negatively
correlated with PN andMES signatures, respectively (Figure 1B).
To validate our above analyses using the TCGA dataset (Figures
1A and 1B), we examined the expression of GPR56 along with
MES markers via immunohistochemistry in an independent
cohort of human GBM specimens (Ohio State University dataset
[Mao et al., 2013]). In this cohort, samples with a high expression
of GPR56 had lower levels of ALDH1A3, a well-established MES
marker (Mao et al., 2013). Conversely, GBMs with a low expres-
sion of GPR56 were highly immunoreactive for ALDH1A3 (Fig-
ure 1C). Interestingly, GPR56 is downregulated in recurrent
GBMs (Figure 1D), which, in many cases, have undergone a shift
toward an MES subtype (Phillips et al., 2006; Wang et al., 2016,
2017). Taken together, our results imply that GPR56 negatively
correlates with the MES subtype and may be downregulated
during MES differentiation in GBMs.
GPR56 Is Highly Expressed in PN-GICs and
Downregulated during Their MES Transition in
Response to TNF-a
We next analyzed whether GICs show similar patterns of GPR56
expression to those observed in clinical specimens. We
compared the levels of GPR56 mRNA in PN- versus MES-GIC
lines in the following two independent datasets: GEO:
GSE49009 (Bhat et al., 2013) and GEO: GSE67089 (Mao et al.,
2013). GEO: GSE49009 contains 11 PN-GICs and 6 MES-
GICs. GEO: GSE67089 contains 6 PN-GICs and 4 MES-GICs.
In both datasets, we observed that GPR56 mRNA levels were
significantly higher in PN-GICs than in MES-GICs (Figure 2A).
To further study the differential expression of GPR56 in
PN versus MES subtypes, we sorted GIC lines into CD44high
and CD44low subpopulations (Figure S2A), which have previ-
ously been shown to be enriched in MES and PN subtypes,
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Figure 1. GPR56 Is Downregulated in
MES-GBMs and Inversely Correlated with
MES Markers
(A) GPR56 mRNA expression comparison across
the five different subtypes of GBM (TCGA data-
set). Gene expression data were obtained from
Brennan et al. (2013) (Table S1). Differences in
GPR56 expression among subtypes were as-
sessed by a Kruskal-Wallis rank-sum test (Dunn’s
post hoc multiple comparison test: MES versus
classical and proneural, p < 0.0001; MES versus
G-CIMP, p < 0.001; MES versus neural, p < 0.01).
In the box-plots, the horizontal line indicates the
median, boundaries of the box indicate the first
and third quartiles, and whiskers indicate confi-
dence intervals (95%). See also Figure S1 and
Table S1.
(B) Correlation plots between GPR56mRNA levels
and proneural (upper panel) or mesenchymal
(lower panel) signature scores in GBM patients
from the TCGA dataset. Pearson’s correlation co-
efficients and p values are indicated in each plot.
(C) Immunohistochemistry of GPR56 and the MES
marker ALDH1A3 in two representative paraffin-
embedded human GBM specimens from the Ohio
State University cohort (n = 24). Scale bar, 80 mm.
(D) GPR56 mRNA expression comparison be-
tween primary and recurrent GBMs (TCGA data-
set). Differences in GPR56 expression were as-
sessed by Kruskal-Wallis rank sum test (Dunn’s
post hoc multiple comparison test: primary versus
recurrent, ***p = 0.002). In the box-plots, the hori-
zontal line indicates the median, boundaries of
the box indicate the first and third quartiles, and
whiskers indicate confidence intervals (95%).respectively (Bhat et al., 2013; Mao et al., 2013), and analyzed
the expression levels of GPR56 in these cells. An RT-qPCR
and western blot analysis revealed that GPR56 was weakly ex-
pressed in CD44high GICs, whereas it was highly enriched in
CD44low GICs (Figures 2B and 2C). Furthermore, we obtained
similar results using ALDH1A3, which is another MES-GBM
marker (Mao et al., 2013). GPR56 mRNA expression was low in
ALDH1A3high GICs, while it was upregulated in ALDH1A3low
GICs (Figures 2D and S2B).
The pro-inflammatory cytokine tumor necrosis factor alpha
(TNF-a) has been shown to induce MES differentiation in GICsCell Report(Bhat et al., 2013). Because GPR56 is
poorly expressed in MES-GICs, we next
asked whether TNF-a treatment downre-
gulates GPR56 expression in PN-GICs.
Indeed, TNF-a promoted a decrease in
GPR56 mRNA expression in all of the
PN-GIC lines tested (Figures 2E and
S2C) while increasing CD44 mRNA
expression (Figure 2E). Moreover, TNF-a
promoted a decrease in GPR56 protein
levels in CD44low cells (Figure 2F). Taken
together, our results show that GPR56
expression is inversely correlated with
a MES phenotype both in GICs andGBM specimens and that GPR56 is downregulated during
TNF-a-mediated MES differentiation.
Loss of GPR56 Promotes MES Differentiation In Vitro
and In Vivo
Given our observations that GPR56 is downregulated during the
MES differentiation of PN-GICs, we asked whether GPR56 is
functionally involved in this process. To test our hypothesis, we
examined whether GPR56 downregulation is required for CD44
expression by loss-of-function studies in PN-GICs. To this end,
we first used short-hairpin-RNA (shRNA)-mediated knockdowns 21, 2183–2197, November 21, 2017 2185
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Figure 2. GPR56 Is Highly Expressed in PN-GICs and Downregulated during Their MES Transition in Response to TNF-a
(A)GPR56mRNA expression analysis in PN-GICs compared to MES-GICs from the following two independent published datasets: GEO: GSE49009 (Bhat et al.,
2013) (unpaired t test, **p = 0.0026) and GSE67089 (Mao et al., 2013) (unpaired t test, ***p = 0.0002). Scatter plots represent mean ± SEM.
(B) GPR56 mRNA expression was measured by RT-qPCR in different GIC lines sorted into CD44high and CD44low subpopulations. Data are represented as
means ± SEMs of at least three independent experiments (t test, *p < 0.05, **p < 0.01).
(C) Western blot analysis of GPR56 in different GIC lines sorted into CD44high and CD44low subpopulations. GAPDH was used as loading control.
(D)GPR56mRNA expression was measured by RT-qPCR in GICs sorted into ALDHhigh or ALDHlow populations. Data are represented as means ± SEMs of three
independent experiments (t test, **p < 0.005).
(E) GPR56 and CD44 mRNA expression was measured by RT-qPCR in CD44low GIC2 and GIC7 treated with or without TNF-a (10 ng/mL for 96 hr). Data are
represented as means ± SEMs of at least three independent experiments (t test, *p < 0.05).
(F) Western blot analysis of GPR56 in CD44low GICs treated with or without TNF-a (10 ng/mL for 24 hr). GAPDH was used as a loading control.
See also Figure S2.of GPR56 in CD44low PN-GICs (Figures S3A and S3B). In linewith
our previous results, knockdown of GPR56 in CD44low cells led
to an increase in CD44 expression both at the mRNA and protein
levels (Figures 3A and 3B). Interestingly, the TNF-a-mediated
increase in CD44 expression was enhanced by GPR56
knockdown (Figures 3A and 3B), thereby suggesting that2186 Cell Reports 21, 2183–2197, November 21, 2017GPR56 inhibits the expression of the MES marker CD44. To
rule out off-target effects of the GPR56 shRNA, we obtained
GPR56-knockout-GIC lines by CRISPR/Cas9 gene editing in
CD44low PN-GICs (Figure S3C). In agreement with the GPR56
knockdown experiments, knockout of GPR56 also promoted
an increase in CD44 expression both at the mRNA and protein
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Figure 3. Loss of GPR56 Promotes CD44 Enrichment and MES Differentiation In Vitro and In Vivo
(A) CD44 mRNA expression was measured by RT-qPCR in CD44low control (CTRL) or GPR56 knockdown (SH5) GICs treated with or without TNF-a for 4 days.
Data are represented as means ± SEMs of at least three independent experiments (t test, **p < 0.01).
(B) Fluorescence activated cell sorting (FACS) analysis of CD44-positive cells in CD44low GPR56 knockdown or control GICs treated with or without TNF-a for
4 days. Data are represented as means ± SEMs of at least three independent experiments (t test, *p < 0.05, **p < 0.01).
(C) Left: CD44mRNA expression was measured by RT-qPCR in GPR56 knockout or parental GIC7 (knockout clone KO5 is shown). Right: FACS analysis of the
percentage of CD44high cells in GPR56 knockout or parental GIC7. Data are represented as means ± SEMs of three independent experiments (t test, *p < 0.05).
(legend continued on next page)
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levels (Figures 3C, S3C, and S3D). To investigate the effect of
GPR56 knockdown on CD44 levels in vivo, we injected GPR56
knockdown or control GICs into the cerebrum of immunocom-
promised mice. Orthotopic tumors formed by intracranial
injection of GPR56 knockdown-GICs expressed higher levels
of CD44 than did control GIC-induced tumors (Figure 3D).
To further test whether GPR56 suppresses MES differentia-
tion, we examined the expression of melanoma cell adhesion
molecule (MCAM), which is another MES marker, in response
to GPR56 knockdown. Concordantly, GPR56 knockdown
GICs expressed higher levels of MCAM protein than did
control GICs (Figure S3E), similar to what was observed with
CD44. Likewise, the effect of GPR56 knockdown on MCAM
expression was enhanced by the presence of TNF-a (Fig-
ure S3E). Taken together, our results show that GPR56 knock-
down in PN-GICs promotes the expression of the MES markers
CD44 and MCAM.
To examine the general role of GPR56 as an inhibitor of MES
differentiation, we next induced GPR56 knockdown in a CL-
GIC cell line. As in PN-GICs, GPR56 knockdown in CL-GICs pro-
moted an increase in CD44 expression both at the mRNA and
protein levels (Figure S3F).
To further characterize the globalMES transcriptional program
induced by GPR56 knockdown, we performed a whole-genome
microarray analysis of gene expression of paired GPR56 knock-
down GICs and control GICs. A paired, two-class significance
analysis of microarrays (SAMs) (Tusher et al., 2001) identified
117 genes that were differentially expressed between knock-
down and control cells (53 upregulated and 64 downregulated)
(Table S2). As expected, GPR56 was significantly downregu-
lated in the knockdown samples. In a gene set enrichment anal-
ysis (GSEA) (Subramanian et al., 2005) using two previously pub-
lished PN and MES signatures (Phillips et al., 2006; Verhaak
et al., 2010), we observed that GPR56 knockdown GICs were
positively enriched for genes in the MES gene sets and,
conversely, negatively enriched in PN genes (Figure 3E). This
same pattern emerged in a GSEA using KO5-GIC microarray
datasets wherein a positive association with MES genes and a
negative association with PN genes were observed in GPR56
knockout GICs (Figure 3F). These results further support the
notion that GPR56 is an inhibitor of MES differentiation in GICs.
We confirmed the global alteration in gene expression that
was shown via a GSEA of microarray data using an RT-qPCR
analysis of a previously reported MES gene set (Bhat et al.,
2013). Most MES genes were upregulated upon GPR56 knock-
down in CD44low GICs (Figure S4A). Interestingly, the GPR56
knockdown-induced increase in MES gene expression was
larger than that induced by TNF-a treatment alone (Figure S4B).
The induction of the MES signature upon GPR56 knockdown
was also observed in unsorted GICs although to a much lesser(D) Immunohistochemistry of CD44 in orthotopic tumors induced by intracranial
promised nude mice. Representative stainings of four injected mice per group a
(E) GSEA enrichment plots of MES and PN signatures (TCGA-Verhaak and Phill
(NES) and FDR are shown for each plot.
(F) GSEA enrichment plots of MES and PN signatures (TCGA-Verhaak and Phi
each plot.
See also Figures S3–S5 and Table S2.
2188 Cell Reports 21, 2183–2197, November 21, 2017extent, thus suggesting that GPR56 loss mainly affects the
CD44low population (Figure S5A). Moreover, the increase in
MES gene expression was enhanced in GPR56 knockdown cells
in the presence of TNF-a (Figure S5B). In agreement with the
GPR56 knockdown data, we observed that most MES markers
were also upregulated in GPR56 knockout GICs (Figure S5C).
Furthermore, GPR56 knockdown in CL-GICs also induced an in-
crease in gene expression of several MES markers (Figure S5D).
Taken together, our results suggest that GPR56 may be a gen-
eral inhibitor of MES differentiation in non-MES GICs including
PN- and CL-GICs.
Knockdown of GPR56 Promotes Radioresistance
In Vitro and In Vivo
We next interrogated whether GPR56 also regulates properties
that are associated with a MES phenotype. MES differentiation
has been linked to resistance to therapy. Several EMT inducers,
such as NF-kB or ZEB1, are associated with increased radiore-
sistance or chemoresistance (Bhat et al., 2013; Siebzehnrubl
et al., 2013). Therefore, we asked whether GPR56 is involved
in the acquisition of radioresistance.
Because ionizing radiation (IR) has been shown to induce PMT
(Halliday et al., 2014; Mao et al., 2013), we first examined
whether IR enhances MES differentiation in our PN-GIC cultures
by measuring the expression of the MES marker MCAM. As
expected, control-GICs upregulated MCAM expression in
response to IR. Interestingly, the IR-induced increase in MCAM
expression was enhanced in GPR56 knockdown GICs (Fig-
ure 4A), analogously to the increased MES differentiation upon
GPR56 knockdown in TNF-a-treated GICs (Figure S3E).
Next, we examined whether knockdown of GPR56 was suffi-
cient to lead to radioresistance. In response to IR, PN-GICs usu-
ally undergo a profound arrest in G2/M (Bhat et al., 2013; Mir
et al., 2010). On the contrary, MES-GICs only display a modest
arrest in G2/M upon exposure to IR, which was correlated with
a faster ability to repair DNA damage as measured by g-H2AX
foci formation (Bhat et al., 2013). Concordant to the acquisition
of aMES phenotype in GPR56 knockdown GICs, the percentage
of cells in G2/M after IR was significantly lower in GPR56 knock-
down GICs than in control GICs (Figure 4B). We then measured
the kinetics of g-H2AX foci formation and repair in GPR56 knock-
down GICs versus control GICs. Although both cell lines showed
comparable g-H2AX foci formation at early time-points, GPR56
knockdown GICs showed an enhanced repair ability 24 and
48 hr after IR exposure (Figure 4C).
Finally, to test whether GPR56 knockdown GICs have
increased radioresistance in vivo, we examined the effect of
clinically relevant fractionated doses of IR (2.5 Gy 3 4) on
orthotopic tumors induced by intracranial injection of control
or GPR56 knockdown GICs in immunocompromised mice.injection of control or GPR56 knockdown GICs into the brain of immunocom-
re shown. Scale bar, 100 mm.
ips) in GPR56 knockdown versus control GICs. Normalized enrichment score
llips) in GPR56 knockout versus parental GICs. NES and FDR are shown for
BC D
A Figure 4. Knockdown of GPR56 Promotes
Radioresistance
(A) FACS analysis of MCAM-positive cells in
GPR56 knockdown GICs or control GICs after
exposure to 6 Gy ionizing radiation (IR). Data are
represented as means ± SEMs of at least three
independent experiments (t test, ***p < 0.001).
(B) Cell cycle analysis of GPR56 knockdown- and
control-GICs. Left: cell cycle plots. The percentage
of cells in G2/M phase is indicated within each plot.
Right: percentages of cells in G2/M in GPR56
knockdown or control GICs. Data are represented
as means ± SEMs of at least three independent
experiments (ANOVA, ***p < 0.0001).
(C) g-H2AX foci formation assay of GPR56
knockdown or control GICs 24 or 48 hr after
exposure to 3 Gy IR. Data are represented as
means ± SEMs of 15–16 technical replicates of
two independent experiments (t test, ***p < 0.001).
(D) Kaplan-Meier survival curves of mice implanted
with GPR56 knockdown or control GIC2 and
treated with or without fractioned intracranial ra-
diation (2.5 Gy 3 4). A log-rank test was used
to assess statistical significance (p = 0.0015).Control-GIC-injected animals had higher survival rates than did
GPR56-knockdown-tumor-bearing mice. The former showed a
slightly improved median survival upon IR treatment, although
it was not statistically significant (Figure 4D). Interestingly, IR
treatment exacerbated the poor survival rates of GPR56-knock-
down-GIC-injected mice, thereby suggesting that GPR56
knockdown GICs are highly radioresistant (Figure 4D). Taken
together, these results suggest that GPR56 silencing promotes
he radioresistance of PN-GICs both in vitro and in vivo.
GPR56PreventsMESDifferentiation by Inhibiting NF-kB
Signaling
The NF-kB signaling pathway is one of the main regulators of the
MES differentiation in response to TNF-a (Bhat et al., 2013; Ed-
wards et al., 2011). Since we observed that the TNF-a-induced
MESdifferentiation is enhanced byGPR56 knockdown, we inter-
rogated whether GPR56 interferes with NF-kB signaling. In tran-
scriptional assays using a luciferase reporter controlled byCell ReportNF-kB binding sites, GPR56 knockdown
GICs displayed higher NF-kB activity
than did control cells, thereby suggesting
that GPR56 inhibits NF-kB-dependent
transcriptional activity (Figure 5A).
To further understand the mechanisms
by which GPR56 inhibits NF-kB activity,
we analyzed the levels of nuclear factor
kappa B inhibitor, alpha (IkBa), a canoni-
cal inhibitor of the NF-kB signaling
pathway (Gilmore, 2006). Interestingly,
GPR56 knockdown GICs expressed
lower levels of IkBa than did control
GICs (Figure 5B). In addition, while
TNF-a decreased IkBa levels in control-
GICs as expected, the TNF-a-inducedreduction of IkBa was enhanced in GPR56 knockdown GICs.
These results are in agreement with the synergistic effects of
TNF-a and GPR56 knockdown that have been observed on the
MES phenotype. We next tested the effect of a constitutively
active form of IkBa in the context of GPR56 knockdown
(Figure S6A). IkBa super repressor (IkB-SR) is a mutant that
cannot be degraded by phosphorylation in response to NF-kB
agonists. The induction of CD44 by TNF-a was significantly
inhibited by IkB-SR both in control GICs and GPR56
knockdown GICs. Furthermore, GPR56 shRNA was not able
to increase CD44 expression in the presence of IkB-SR, indi-
cating that GPR56 inhibits NF-kB signaling upstream of IkBa
(Figures 5C and S6B). Therefore, these results suggest that
GPR56 might inhibit NF-kB signaling by increasing the levels of
IkBa protein.
IkBa protein levels are regulated by the IKK complex, which
phosphorylates IkBa and targets it for proteasomal degradation.
IKKg/NF-kB essential modulator (NEMO) is the regulatorys 21, 2183–2197, November 21, 2017 2189
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Figure 5. GPR56 Prevents MES Differentiation by Inhibiting NF-kB Signaling
(A) Luciferase activity assay of GPR56 knockdown or control GICs treated with or without TNF-a. Data are represented as means ± SEMs of at least three in-
dependent experiments (t test, *p < 0.05, **p < 0.01, ***p < 0.005).
(B) Western blot analysis of IkBa protein levels in CD44low GPR56 knockdown or control GICs treated with or without TNF-a. Tubulin was used as loading control.
(C) FACS analysis of CD44-positive cells in control or GPR56 knockdown GICs (GIC2) infected with control or IkB-SR adenoviruses. Adenoviral infection was
performed 24 hr prior to TNF-a treatment for an additional 72 hr. Data are represented as means ± SEMs of at least three independent experiments (t test,
*p < 0.05).
(D) FACS analysis of CD44-positive cells in control or GPR56 knockdown GICs stably transduced with NEMO shRNA-encoding lentiviruses and treated with or
without TNF-a. Data are represented as means ± SEMs of at least three independent experiments (t test, *p < 0.05, **p < 0.01).
(legend continued on next page)
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subunit of the IKK complex. To interrogate whether GPR56 sta-
bilizes IkBa protein by inhibiting the IKK complex, we tested the
effect of GPR56 loss in NEMO knockdown GICs (Figure S6C).
TNF-a did not induce CD44 expression in NEMO knockdown
GICs, as expected for an upstream activator of the NF-kB
signaling pathway. In addition, GPR56/NEMO knockdown
GICs had similar levels of CD44 as those of control cells both
in the absence or presence of TNF-a, indicating that GPR56
inhibits NF-kB signaling upstream of NEMO (Figure 5D).
In summary, our results suggest that GPR56 inhibits NF-kB
signaling by inhibiting the IKK complex and, thereby, stabilizing
IkBa protein levels. We propose amodel in which GPR56 inhibits
NF-kB signaling in PN-GICs in the basal state. DuringMESdiffer-
entiation, TNF-a directly activates the NF-kB pathway (direct
pathway) while also promoting a decrease in GPR56 expression.
The latter effect releases the GPR56-mediated IKK inhibition,
thereby enhancing NF-kB pathway activation (indirect pathway)
(Figure 5E).
Low GPR56 Is a Poor Prognostic Factor in Non-G-CIMP
GBM Patients
To test whether our results in experimental cellular and mouse
models might be translated to human GBMs, we analyzed
whether a GPR56-associated signature correlates with overall
survival (OS) or disease-free survival (DFS) in GBM patients of
the TCGA dataset. A gene-expression-based signature associ-
ated with a low expression of GPR56 was derived using the
117 differentially expressed genes in control versus GPR56
knockdown GICs. This signature was applied onto the TCGA
gene expression dataset (Brennan et al., 2013) by calculating a
low GPR56-associated signature score for each GBM patient
in the dataset (see Experimental Procedures). Interestingly,
GBM patients (G-CIMP and non-G-CIMP) with a low GPR56-
associated signature displayed shorter OS and DFS than did pa-
tients whose tumors had a high GPR56-associated signature
(Figure 6A). To exclude the possibility that G-CIMP tumors that
were included in the analysis were responsible for the improved
survival phenotype, we also analyzed this signature only within
non-G-CIMP GBMs. Importantly, the low GPR56-associated
signature was also correlated with poor survival in non-G-
CIMP GBMs (Figure 6B). Median OS was shorter in non-G-
CIMP tumors with a low GPR56-associated signature versus
GBMs with a high GPR56-associated signature. Median DFS
was also shorter in non-G-CIMP GBMs with a low GPR56-asso-
ciated signature.
To validate these results in an independent dataset, we
analyzed the correlation of GPR56 levels (as measured by immu-
nohistochemistry) with survival in GBM patients from the Ohio
State University dataset (Mao et al., 2013). In line with the results
obtained with the TCGA dataset, GBM patients with high levels
of GPR56 displayed increased OS compared with that of those
with low or intermediate levels of GPR56 protein (Figure 6C).(E) Proposed molecular interactions between GPR56 and NF-kB signaling. In the
TNF-a activates NF-kB signaling, thereby promoting the transcriptional activatio
GPR56 downregulation, thereby relieving GPR56-mediated NF-kB inhibition and
See also Figure S6.Taken together, our results suggest that GBM patients with
low GPR56 expression have a worse prognosis, which might
be explained by the increased radioresistance of GPR56low-
GICs in these tumors.
According to the low expression ofGPR56 in MES-GBMs (Fig-
ure 1A), these tumors displayed a high score for the low GPR56-
associated signature compared with the rest of GBM subtypes
(Figure 6D). These results further support the notion that MES-
GBMs have worse prognosis than do non-MES-GBMs.
A Low GPR56-Associated Signature Is Associated
with MES Signatures across Multiple Tumor Types
beyond GBM
To interrogate whether GPR56 might also inhibit MES differenti-
ation in other tumor types, we analyzed the expression of the low
GPR56-associated signature across 25 different tumor types
(TCGA datasets) and correlated this signature with 414 previ-
ously published oncogenic signatures (Prat et al., 2015). Strik-
ingly, we found a significant correlation between the low
GPR56-associated signature and signatures related to MES
phenotypes, such as CD44+ breast cancer stem cells (Creighton
et al., 2009) or EMT (Taube et al., 2010), in the great majority of
tumors (Figures 7A and 7B). Conversely, the low GPR56-associ-
ated signature was negatively correlated with signatures related
to epithelial differentiation (Prat et al., 2010) and proliferation (Fan
et al., 2011; Prater et al., 2014; Wirapati et al., 2008) (Figures 7A
and 7B). Interestingly, there was a positive correlation between
the low GPR56-associated signature and inflammatory signa-
tures (Iglesia et al., 2016; Iglesia et al., 2014; Rody et al., 2009;
Van Laere et al., 2013), which correlates with the increased in-
flammatory infiltrates in MES-like tumors. From these results,
we infer that GPR56 might have a general role as an inhibitor
of the MES transition across multiple tumor types beyond
GBM, presumably through the inhibition of NF-kB signaling.
Furthermore, we also performed a pan-cancer survival anal-
ysis of tumors with a low GPR56-associated signature (12 tumor
types; TCGA datasets). Impressively, the lowGPR56-associated
signature had a prognostic value in the following four tumor
types: breast cancer (BRCA), GBM, lung squamous cell carci-
noma (LUSC), and uterine corpus endometrioid carcinoma
(UCEC). As in GBM patients, LUSC patients whose tumors ex-
pressed high levels of the low GPR56-associated signature
had a poor prognosis. Conversely, a low GPR56-associated
signature was predictive of better outcomes in BRCA and
UCEC. These results suggest that GPR56 might have a major
role in the biology of cancer cells in a broad range of tumor types.
DISCUSSION
GBMs are highly plastic and have an inherent tendency to tran-
sition from one subtype to another (Bhat et al., 2013; Kupp et al.,
2016; Lu et al., 2016; Mao et al., 2013). This transcriptionalbasal state, GPR56 inhibits the NF-kB signaling pathway upstream of NEMO.
n of mesenchymal genes (direct pathway). At the same time, TNF-a promotes
enhancing MES differentiation (indirect pathway).
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Figure 6. Low GPR56-Associated Signature Correlates with Poor Survival in Human GBM
(A) Kaplan-Meier curves showing (left) overall survival (OS) and (right) disease-free survival (DFS) of GBMs (G-CIMP and non-G-CIMP) enriched in the lowGPR56-
associated signature (low GPR56 signature) versus GBMs with low expression of this signature (high GPR56 signature) (TCGA dataset).
(B) Kaplan-Meier curves showing OS (left) and DFS (right) of non-G-CIMP GBMs enriched in the low GPR56-associated signature versus GBMs with low
expression of this signature (TCGA dataset).
(A and B) Patients were divided into two groups (high or low GPR56 signature) according to their low GPR56-associated signature score (cutoff: median of the
signature score).
(legend continued on next page)
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plasticity empowers GBMs with the capability to adapt to treat-
ment and develop resistance to therapy and holds the key to
understand the extreme resilience of GBMs to any oncologic
treatment. The identification of the molecular mechanisms that
control transitions from one subtype to another is crucial to
understand GBM natural evolution and acquired resistance to
therapy. In this study, we identified GPR56/ADGRG1 as an inhib-
itor of the MES transition in GICs. GPR56 is an adhesion GPCR
with a prominent role in NSC and OPC proliferation and differen-
tiation (Ackerman et al., 2015; Bae et al., 2014; Giera et al., 2015)
and is highly expressed in PN and CL GBMs (Figure 1A). These
findings are in agreement with the proposed role of NSCs or
OPCs as the cells of origin of PN-GBMs (Alcantara Llaguno
et al., 2015; Liu et al., 2011) and with an NSC-like behavior of
CL-GICs (Kupp et al., 2016). Our study highlights the central
role in GBM pathogenesis of factors that control normal neural
progenitor functions.
MES differentiation in GBMs is associated with increased
radioresistance (Bhat et al., 2013), and accordingly, we also
showed that GPR56 inhibits radioresistance. In addition, we
identified a low GPR56-associated signature that is prognostic
of a poor outcome in non-G-CIMP GBM patients who were
treatedwith radiotherapy. Therefore, our studiesmight represent
a starting point in designing gene-expression-based diagnostic
tools to predict the GBM response to radiotherapy. Hyperactiva-
tion of NF-kB signaling has been associated with MES-subtype
GBMs (Bhat et al., 2013; Verhaak et al., 2010). Therefore, the
NF-kB pathway is regarded as a promising target for drug devel-
opment in many cancer types including MES-GBMs (Prasad
et al., 2010). Mechanistically, we uncovered that GPR56 inhibits
canonical NF-kB signaling by inhibiting the IKK complex and,
thus, stabilizing IkBa protein levels. Given the GPR56/NF-kB
signaling link, and since GPR56 is a member of the Adhesion-
GPCR class, our study robustly provides a druggable therapeu-
tic target in the development of adjuvant therapies to overcome
radioresistance in GBM and possibly other cancers. Further-
more, the identification of the GPR56/NF-kB signaling axis
may have important consequences in other fields beyond cancer
biology where NF-kB and GPR56 have major regulatory roles,
such as innate and adaptive immunity or neural progenitor
biology (Ackerman et al., 2015; Bae et al., 2014; Chang et al.,
2016; Giera et al., 2015; Piao et al., 2004).
The classification of tumors into subtypes with clinical
meaning is of crucial interest for clinical diagnostics as well
as to predict responses to treatments and eventually develop
patient-tailored therapies. The TCGA project identified five
distinct molecular subtypes in GBM according to their gene
expression and epigenetic profiles (Brennan et al., 2013;
Noushmehr et al., 2010; Verhaak et al., 2010). The epigenetic
G-CIMP phenotype is predictive of longer survival (Noushmehr(C) Kaplan-Meier curves showing OS of GBMs displaying either high (n = 9), inte
tochemistry (Ohio State University dataset).
(D) Expression of the low GPR56-associated signature across the different subtyp
(Brennan et al., 2013). Shown is a boxplot diagram of the lowGPR56-associated s
low GPR56-associated signature score among subtypes were assessed with the
versus each of the other subtypes, p < 0.0001). In the box-plots, the horizontal line
and whiskers indicate confidence intervals (95%).et al., 2010). Conversely, MES-related gene signatures have
been associated with higher GBM aggressiveness although
most studies have included G-CIMP tumors (Cheng et al.,
2012; Gerber et al., 2014; Kim et al., 2013), which are associ-
ated with a PN (non-MES) phenotype and might have been a
confounding factor in these studies. In a step further, we pre-
viously showed a significant correlation between a MES com-
posite metagene and shorter survival or radioresistance in
patients with IDH wild-type GBMs, which largely overlap with
the non-G-CIMP group (Bhat et al., 2013). Recently, Wang
et al. (2017) have refined the GBM-intrinsic transcriptional
subtype classification and confirmed that, among primary
and recurrent IDH wild-type GBMs, the MES subtypes had
the worst prognosis. Importantly, in this study, we found that
a low GPR56-associated signature is associated with a
poor patient prognosis within non-G-CIMP GBMs. Because
GPR56 is an important player in MES differentiation, our
results strengthen the idea that gene signatures that are asso-
ciated with MES features may be clinically used to predict
GBM patient survival and highlight the great importance of
understanding the molecular mechanisms that regulate MES
differentiation. Noticeably, we showed that a functional signa-
ture (low GPR56 signature) that is linked to a biologically
relevant signaling pathway has a robust prognostic value.
These results highlight the fact that understanding the biology
behind the different GBM subtypes is crucial to predict tumor
behavior at the clinical level.
In a pan-cancer analysis, we showed that the low GPR56-
associated signature was positively correlated with MES signa-
tures, and it even had a prognostic value in other tumor types
beyond GBM (Figure 7). Strikingly, GPR56 is downregulated in
claudin-low breast tumors, which are associated with poorer
prognosis and display features of MES and inflammatory pheno-
types (Prat et al., 2010). Our results suggest that GPR56 might
have a general regulatory role in cancer cell biology, presumably
through the maintenance of the epithelial state and the inhibition
of a MES fate. Further studies addressing the function of GPR56
in other tumor types are required to test this hypothesis.EXPERIMENTAL PROCEDURES
Cell Culture and Treatments
Cell cultures that were enriched in GICs were obtained from human GBM
specimens as described previously (Alonso et al., 2011; Galli et al., 2004)
and subsequently cultured on laminin-coated plates (10 mg/mL; Sigma) and
maintained in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12
(DMEM/F12; GIBCO) supplemented with N2 (GIBCO), basic fibroblast growth
factor, and epidermal growth factor (20 ng/ml; GIBCO) at 37C, 5% CO2, and
5% oxygen. Lentiviral or retroviral transduction was performed by treating
cells with the purified viral suspension for 4 hr. Cells were selected with the
appropriate drug 48 hr post-infection. For cytokine treatment, GICs werermediate (n = 10), or low (n = 5) levels of GPR56 as assessed by immunohis-
es of GBMwas calculated using gene expression data from the TCGA dataset
ignature score for each GBMpatient in the dataset (Table S2). Differences in the
Kruskal-Wallis rank sum test (Dunn’s post hoc multiple-comparison test: MES
indicates themedian, boundaries of the box indicate the first and third quartiles,
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Figure 7. A Low GPR56-Associated Signa-
ture Correlates with MES Signatures across
Different Tumor Types
(A) Correlations between the low GPR56-associ-
ated signature and each of 414 gene signatures
from the University of North Carolina (UNC) data-
base (Table S3; Prat et al., 2015) across 25
different tumor types (TCGA datasets). Shown
is a clustered heatmap of Pearson’s correlation
coefficient values. Acronyms of tumor types are
described in Table S3.
(B) Representative individual correlation plots be-
tween the low GPR56-associated signature and
selected gene signatures (epithelial differentiation
(UNC_Differentiation.Score_Model_BCR.2010) or
CD44+ breast cancer stem cells (UNC_MS_
CD44_UP_Median_PNAS.2009) in either breast
cancer (BRCA) or lung squamous cell carcinoma
(LUSC), respectively. Pearson’s correlation co-
efficients and p values are shown within each plot.
(C)Pan-cancer survival analysis of tumorswitha low
GPR56-associated signature. The plot shows the
overall survival hazard ratios of patients whose tu-
mors express high levels of the low GPR56-asso-
ciated signature. The size of the square is inversely
proportional to the SE. Horizontal bars represent
95% CIs of hazard ratios. In blue, the associations
were found to be statistically significant.
See also Table S3.treated with 10 ng/mL of TNF-a (Peprotech) for different time periods as
indicated in figure legends.
Orthotopic Xenograft Models
A total of 13 105 GICs constitutively expressing luciferase were injected intra-
cranially into the right striatum of 4–6 week-old male athymic nude mice anes-
thetized with ketamine and xylacine. Stereotaxic coordinates used were
0.5 mm lateral, 2 mm anterior from the bregma, and 3 mm deep. Intracranial
tumor growth was monitored by non-invasive bioluminescence imaging using
the Aequoria MDS system (Hamamatsu). When appropriate, mice were
sacrificed, and brain sections were stained with H&E and subjected to immu-
nohistochemistry. All animal procedures were reviewed and approved by the
Institutional Animal Care and Use Committee at the University of Barcelona.
For the in vivo irradiation experiments, GICswere implanted intracranially us-
ing the guide-screw system in 4–5 week-old athymic nude mice (male/female
randomized). After 1 week of guide-screw implantation, 53 1105 cells were in-
jected intracranially in eachmouse and randomly distributed between groups. A
minimum of five mice was used in each group. Kinetics of tumor growth were
monitored using IVIS 200 system bioluminescent imaging, and tumor volume2194 Cell Reports 21, 2183–2197, November 21, 2017was measured using Living Image 4.1 software. IR
was delivered using fractionated doses (2.5 Gy 3
4) using a 60Co teletherapy unit and a custom gig
with validated dosimetry. Mice that presented
neurological symptoms (i.e., hydrocephalus, sei-
zures, inactivity, or ataxia) or that were moribund
were sacrificed, and brains were fixed in formalin
and stained with H&E to confirm the presence of a
tumor. All animal procedures were reviewed and
approved by the Institutional Animal Care and Use
Committee at the M.D. Anderson Cancer Center.
Bioinformatic Analysis of Microarray Data
To identify genes that were differentially ex-
pressed across groups, normalized microarraydata were analyzed using a multiclass SAM (Tusher et al., 2001). The low
GPR56-associated signature was defined as the 117 genes that were differ-
entially expressed between GPR56 knockdown and control cells (53 upregu-
lated and 64 downregulated; Table S2). To obtain an enrichment score that
was related to the low GPR56-associated signature for each sample or pa-
tient, the SAM score of each gene in the signature was multiplied by its
expression value in the tested sample, and all these values were summed
up to give a single score as described in Go´mez-Miragaya et al. (2017)
and Keller et al. (2012).
Statistical Analysis
Two-tailed Student’s t test (to compare two experimental groups) or an
ANOVA (to compare three or more groups) were performed for data analysis
using GraphPad Prism (GraphPad Software). A Kruskal-Wallis test was used
for gene expression data analysis fromGBMpatients (TCGA dataset), whereas
a log-rank analysis was performed to determine the statistical significance of
Kaplan-Meier survival curves using the R statistics software (The R Project for
Statistical Computing). For all statistical methods, p < 0.05 was considered
significant.
DATA AND SOFTWARE AVAILABILITY
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